Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1197) 1197
Paper (718) 718
Publication (427) 427
Newspaper Article (226) 226
Report (121) 121
Conference Proceeding (26) 26
Book / eBook (20) 20
Book Review (19) 19
Patent (10) 10
Dissertation (9) 9
Book Chapter (2) 2
Data Set (1) 1
Electronic Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experiment (763) 763
particle physics (710) 710
physics (683) 683
high energy physics - experiment (680) 680
physics - high energy physics - experiment (660) 660
high energy physics (506) 506
phenomenology (319) 319
particle physics - experiment (310) 310
nuclear experiment (238) 238
hep (237) 237
cern lhc coll (222) 222
experimental results (211) 211
physics of elementary particles and fields (211) 211
physical sciences (175) 175
fysik (174) 174
natural sciences (152) 152
naturvetenskap (152) 152
subatomic physics (134) 134
subatomär fysik (134) 134
scattering [p p] (126) 126
astrophysics (108) 108
atlas (108) 108
colliding beams [p p] (105) 105
hadron-hadron scattering (104) 104
8000 gev-cms (101) 101
p p: scattering (100) 100
index medicus (96) 96
high energy astrophysical phenomena (93) 93
p p: colliding beams (92) 92
physics, particles & fields (89) 89
13000 gev-cms (80) 80
hep-ex (80) 80
humans (75) 75
science & technology (73) 73
elementary particles, quantum field theory (68) 68
quantum field theories, string theory (68) 68
female (60) 60
collisions (57) 57
male (56) 56
background (51) 51
large hadron collider (50) 50
settore fis/01 - fisica sperimentale (50) 50
settore fis/04 - fisica nucleare e subnucleare (49) 49
物理学 (49) 49
detectors (48) 48
astronomy, astrophysics and cosmology (43) 43
measurement science and instrumentation (41) 41
ciências físicas [ciências naturais] (40) 40
middle aged (40) 40
nuclear energy (40) 40
nuclear physics, heavy ions, hadrons (40) 40
nuclear and particle physics. atomic energy. radioactivity (36) 36
medicine, general & internal (35) 35
analysis (33) 33
ex (32) 32
instrumentation and detectors (32) 32
transverse momentum dependence (32) 32
adult (31) 31
mass dependence (31) 31
nuclear and high energy physics (31) 31
parton distributions (31) 31
supersymmetry (31) 31
aged (30) 30
astronomy & astrophysics (30) 30
decay (30) 30
rapidity dependence (30) 30
data analysis method (29) 29
luminosity (29) 29
classical and quantum gravitation, relativity theory (28) 28
lhc (28) 28
oncology (28) 28
quantum physics (28) 28
standard model (28) 28
physics and astronomy (26) 26
cern lab (25) 25
engineering (25) 25
settore ing-inf/07 - misure elettriche e elettroniche (25) 25
missing-energy [transverse momentum] (23) 23
model (23) 23
transverse momentum (23) 23
bottom: particle identification (22) 22
sensitivity (22) 22
kinematics (21) 21
animals (20) 20
física (20) 20
leptons (20) 20
measured [differential cross section] (20) 20
nuclear physics (20) 20
transverse momentum: missing-energy (20) 20
jet: bottom (19) 19
nucl (19) 19
regular - experimental physics (19) 19
searching (19) 19
z0: leptonic decay (19) 19
differential cross section: measured (18) 18
final state:jet lepton (18) 18
info:eu-repo/classification/ddc/ddc:530 (18) 18
leptonic decay [z0] (18) 18
pair production [top] (18) 18
physics, nuclear (18) 18
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Diaz, Rafael and Widimsky, Peter and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Keltai, Katalin and Maggioni, Aldo P and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Pogosova, Nana and Ryden, Lars and Fox, Keith A A and Bhatt, Deepak L and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Avezum, Alvaro A and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ... and COMPASS Investigators
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
by Connolly, Stuart J and Eikelboom, John W and Bosch, Jackie and Dagenais, Gilles and Dyal, Leanne and Lanas, Fernando and Metsarinne, Kaj and O'Donnell, Martin and Dans, Anthony L and Ha, Jong-Won and Parkhomenko, Alexandr N and Avezum, Alvaro A and Lonn, Eva and Lisheng, Liu and Torp-Pedersen, Christian and Widimsky, Petr and Maggioni, Aldo P and Felix, Camilo and Keltai, Katalin and Hori, Masatsugu and Yusoff, Khalid and Guzik, Tomasz J and Bhatt, Deepak L and Branch, Kelley R H and Cook Bruns, Nancy and Berkowitz, Scott D and Anand, Sonia S and Varigos, John D and Fox, Keith A A and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and RECH, RAFAEL and ... and COMPASS Investigators and COMPASS investigators
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | ORAL RIVAROXABAN | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
by Herbst, Roy S, Prof and Baas, Paul, Prof and Kim, Dong-Wan, MD and Felip, Enriqueta, MD and Pérez-Gracia, José L, MD and Han, Ji-Youn, Prof and Molina, Julian, MD and Kim, Joo-Hang, Prof and Arvis, Catherine Dubos, MD and Ahn, Myung-Ju, Prof and Majem, Margarita, MD and Fidler, Mary J, MD and de Castro, Gilberto, MD and Garrido, Marcelo, MD and Lubiniecki, Gregory M, MD and Shentu, Yue, PhD and Im, Ellie, MD and Dolled-Filhart, Marisa, PhD and Garon, Edward B, MD
Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | CRITERIA | MEDICINE, GENERAL & INTERNAL | ANTI-PD-L1 ANTIBODY | THERAPY | NSCLC | IMMUNOTHERAPY | PD-L1 | BLOCKADE | NIVOLUMAB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Slopes | Cell survival | Medical treatment | Medical services | FDA approval | Survival | Patients | Medical centres | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Synthesis and Physicochemical Characterization of Multiwalled Carbon Nanotubes/Hydroxamic Alginate Nanocomposite Scaffolds
by Lima, AMF and Lima, MD and Assis, OBG and Raabe, A and Amoroso, HC and Tiera, VAD and de Andrade, MB and Tiera, MJ
JOURNAL OF NANOMATERIALS, ISSN 1687-4110, 2018, Volume 2018, pp. 1 - 12
In this study, the preparation of porous nanocomposite scaffolds (HX-CNT) from a combination of a hydroxamic derivative of alginate (HX) and an... 
MATRIX | HYDROGELS | DESIGN | COMPOSITE SCAFFOLDS | ACID | NANOTUBE COMPOSITES | MATERIALS SCIENCE, MULTIDISCIPLINARY | NANOSCIENCE & NANOTECHNOLOGY | ANGIOTENSIN-CONVERTING ENZYME | MECHANICAL-PROPERTIES | DERIVATIVES | IMMOBILIZATION | Infrared spectroscopy | Fourier transformation | Drug delivery systems | Hydrogels | Toxicity | Hydroxyapatite | Cell adhesion & migration | Biomedical materials | Caustic soda | Polymers | Multi wall carbon nanotubes | Enzymes | Tissue engineering | Mechanical properties | Crosslinking | Modulus of elasticity | Alginates | Raman spectroscopy | Carbon | Physical properties | Studies | Nanocomposites | Sodium | Microscopy | Scaffolds
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
by Gerstein, Hertzel C and Colhoun, Helen M and Dagenais, Gilles and Dagenais, Gilles R and Diaz, Rafael and Diaz, Sarahy and Lakshmanan, Mark and Pais, Prem and Probstfield, Jeffrey and Riesmeyer, Jeffrey S and Riddle, Matthew C and Rydén, Lars and Xavier, Denis and Atisso, Charles Messan and Dyal, Leanne and Hall, Stephanie and Hall, Charles and Rao-Melacini, Purnima and Wong, Gloria and Avezum, Alvaro and Basile, Jan and Chung, Ming-Min and Chung, Namsik and Chung, Jin-Wook and Conget, Ignacio and Cushman, William C and Franek, Edward and Hancu, Nicolae and Hanefeld, Christoph and Hanefeld, Markolf and Holt, Shaun and Jansky, Petr and Keltai, Matyas and Keltai, Katalin and Lanas, Fernando and Leiter, Lawrence A and Lopez-Jaramillo, Patricio and Cardona Munoz, Ernesto German and Pirags, Valdis and Pogosova, Nana and Raubenheimer, Peter J and Shaw, Jonathan E and Sheu, Wayne H-H and Temelkova-Kurktschiev, Theodora and Abella, Mercedes and Alebuena, Andrea and Almagro, Sandra and Amoroso, Eduardo and Anadon, Paula and Andreu, Elizabeth and Aristimuño, Guillermo and Arzadun, Maria and Barbieri, Maria and Barcudi, Raul and Bartolacci, Ines and Bolobanich, Gabriel and Bordonava, Anselmo and Bustamante Labarta, Miguel and Bustos, Betina and Caccavo, Alberto and Camino, Alejandra and Cantero, Maria and Carignano, Maria and Cartasegna, Luis and Cipullo, Marcela and Commendatore, Víctor and Conosciuto, Victoria and Costamagna, Osvaldo and Crespo, Claudia and Cuello, Jose and Cuneo, Carlos and Cusimano, Sandra and Dean, Sofia and Dituro, Claudio and Dominguez, Andrea and Farah, Miguel and Fernandez, Alberto and Fernandez, Florencia and Ferrari, Adriana and Flammia, Patricia and Fuentealba, Jose and Gallardo, Karina Beatriz and Garcia, Mar and Garcia, Celso and Garcia, Maria and Garcia Duran, Ruben and Garrido, Marcelo and Gavicola, Rodolfo and Gerbaudo, Claudio and Gilli, Graciela and Giotto, Ana Paula and Godoy Bolzán, Pedro and Gomez Vilamajo, Oscar and Guerlloy, Fernando and Guridi, Cristian and Gutierrez Garrido, Narcisa and Hasbani, Eduardo and Hermida, Sonia and Hominal, Miguel and Hrabar, Adrian and ... and REWIND Investigators
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk... 
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights